Organon & Co. with ticker code (OGN) have now 7 market analysts covering the stock. The analyst consensus now points to a rating of ‘hold’. The range between the high target price and low target price is between 43 and 23 with the average target price sitting at $31.14. Now with the previous closing price of $20.74 and the analysts are correct then there would likely be a percentage uptick in value of 50.1%. There is a 50 day moving average of $22.62 and the 200 day moving average is $26.09. The total market capitalization for the company now stands at 5.26B. The current stock price for Targa Resources Corp. is currently 20.63 USD
The potential market cap would be $7,900,504,716 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 7.07, revenue per share of 24.17 and a 9.19% return on assets.
Organon & Co. (Organon) is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women’s health, biosimilars and established brands (Organon Products). Organon has a portfolio of contraception and fertility brands, such as Nexplanon or Implanon NXT, NuvaRing, Follistim AQ, and Elonva. The Company’s Biosimilars portfolio spans immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. The Company sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. It operates its manufacturing facilities in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.
